{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:32:05Z","timestamp":1786462325590,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40120-024-00675-w","type":"journal-article","created":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T16:03:54Z","timestamp":1730563434000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Lecanemab\u2019s Path Forward: Navigating the Future of Alzheimer\u2019s Treatment in Europe Amidst the EMA's Rejection"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8456-4169","authenticated-orcid":false,"given":"Alessandro","family":"Martorana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Giuseppina","family":"Bonomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina Gaia","family":"Di Donna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Motta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,2]]},"reference":[{"key":"675_CR1","doi-asserted-by":"publisher","first-page":"q1692","DOI":"10.1136\/bmj.q1692","volume":"386","author":"E Mahase","year":"2024","unstructured":"Mahase E. Lecanemab: European drug agency rejects Alzheimer\u2019s drug amid debate over efficacy and safety. BMJ. 2024;386:q1692.","journal-title":"BMJ."},{"key":"675_CR2","doi-asserted-by":"crossref","unstructured":"van Dyck C, Swanson C, Aisen P, Bateman R, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):142\u20133.","DOI":"10.1056\/NEJMoa2212948"},{"key":"675_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcad175","author":"KY Liu","year":"2023","unstructured":"Liu KY, Villain N, Ayton S, Ackley SF, Planche V, Howard R, et al. Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer\u2019s disease. Brain Commun. 2023. https:\/\/doi.org\/10.1093\/braincomms\/fcad175.","journal-title":"Brain Commun."},{"key":"675_CR4","doi-asserted-by":"crossref","unstructured":"Granzotto A, Sensi SL. Once upon a time, the amyloid cascade hypothesis. Ageing Res Rev. 2024;1(93): 102161.","DOI":"10.1016\/j.arr.2023.102161"},{"issue":"1","key":"675_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0166-2236(97)01168-5","volume":"21","author":"RL Neve","year":"1998","unstructured":"Neve RL, Robakis NK. Alzheimer\u2019s disease: a re-examination of the amyloid hypothesis. Trends Neurosci. 1998;21(1):15\u20139.","journal-title":"Trends Neurosci."},{"key":"675_CR6","doi-asserted-by":"crossref","unstructured":"Jack CR, Therneau TM, Weigand SD, Wiste HJ, Knopman DS, Vemuri P, et al. Prevalence of biologically vs clinically defined Alzheimer spectrum entities using the National Institute on Aging\u2014Alzheimer\u2019s Association Research Framework. JAMA Neurol. 2019;76(10):1174\u201383.","DOI":"10.1001\/jamaneurol.2019.1971"},{"issue":"90","key":"675_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.101996","volume":"1","author":"PF H\u00f8ilund-Carlsen","year":"2023","unstructured":"H\u00f8ilund-Carlsen PF, Revheim ME, Costa T, Alavi A, Kepp KP, Sensi SL, et al. Passive Alzheimer\u2019s immunotherapy: a promising or uncertain option? Ageing Res Rev. 2023;1(90): 101996.","journal-title":"Ageing Res Rev"},{"key":"675_CR8","doi-asserted-by":"crossref","unstructured":"H\u00f8ilund-Carlsen PF, Revheim ME, Costa T, Kepp KP, Castellani RJ, Perry G, et al. FDG-PET versus amyloid-PET imaging for diagnosis and response evaluation in Alzheimer\u2019s disease: benefits and pitfalls. Diagnostics. 2023;13(13):2254.","DOI":"10.3390\/diagnostics13132254"},{"issue":"2","key":"675_CR9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3233\/JAD-230099","volume":"94","author":"KP Kepp","year":"2023","unstructured":"Kepp KP, Sensi SL, Johnsen KB, Barrio JR, H\u00f8ilund-Carlsen PF, Neve RL, et al. The anti-amyloid monoclonal antibody lecanemab: 16 cautionary notes. J Alzheimer\u2019s Dis. 2023;94(2):497\u2013507.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"675_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03158-5","author":"C Pappalettera","year":"2024","unstructured":"Pappalettera C, Carrarini C, Cappa S, Caraglia N, Cotelli M, Marra C, et al. Challenges to identifying risk versus protective factors in Alzheimer\u2019s disease. Nat Med. 2024. https:\/\/doi.org\/10.1038\/s41591-024-03158-5.","journal-title":"Nat Med."},{"issue":"1","key":"675_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s41512-024-00172-6","volume":"8","author":"FL Lombardo","year":"2024","unstructured":"Lombardo FL, Lorenzini P, Mayer F, Massari M, Piscopo P, Bacigalupo I, et al. Development of a prediction model of conversion to Alzheimer\u2019s disease in people with mild cognitive impairment: the statistical analysis plan of the INTERCEPTOR project. Diagn Progn Res. 2024;8(1):11.","journal-title":"Diagn Progn Res."},{"key":"675_CR12","doi-asserted-by":"publisher","first-page":"102203","DOI":"10.1016\/j.arr.2024.102203","volume":"94","author":"I Terao","year":"2024","unstructured":"Terao I, Kodama W. Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer\u2019s disease: a systematic review and network meta-analysis. Ageing Res Rev. 2024;94:102203.","journal-title":"Ageing Res Rev."},{"key":"675_CR13","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/bmj.p1580","volume":"382","author":"E Mahase","year":"2023","unstructured":"Mahase E. Alzheimer\u2019s disease: lecanemab gets full FDA approval and black box safety warning. BMJ. 2023;382:1580.","journal-title":"BMJ."},{"issue":"3","key":"675_CR14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.36150\/2499-6564-N327","volume":"69","author":"F Ronchetto","year":"2021","unstructured":"Ronchetto F, Ronchetto M. Biological diagnosis of Alzheimer\u2019s disease and the issue of stigma. J Gerontol Geriatr. 2021;69(3):195\u2013207.","journal-title":"J Gerontol Geriatr."},{"key":"675_CR15","unstructured":"Medicines and Healthcare products Regulatory Agency. Lecanemab licensed for adult patients in the early stages of Alzheimer\u2019s disease. https:\/\/www.gov.uk\/government\/news\/lecanemab-licensed-for-adult-patients-in-the-early-stages-of-alzheimers-disease. Accessed 29 Aug 2024."},{"key":"675_CR16","unstructured":"NICE. Benefits of new Alzheimer\u2019s treatment lecanemab are too small to justify the cost to the NHS. https:\/\/www.nice.org.uk\/news\/articles\/benefits-of-new-alzheimer-s-treatment-lecanemab-are-too-small-to-justify-the-cost-to-the-nhs. Accessed 29 Aug 2024."},{"key":"675_CR17","doi-asserted-by":"crossref","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks JD, et al. Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327.","DOI":"10.1001\/jama.2023.13239"},{"key":"675_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01507-7","author":"LS Honig","year":"2024","unstructured":"Honig LS, Sabbagh MN, van Dyck CH, Sperling RA, Hersch S, Matta A, et al. Updated safety results from phase 3 lecanemab study in early Alzheimer\u2019s disease. Alzheimers Res Ther. 2024. https:\/\/doi.org\/10.1186\/s13195-024-01507-7.","journal-title":"Alzheimers Res Ther."},{"key":"675_CR19","doi-asserted-by":"publisher","DOI":"10.1523\/ENEURO.0319-23.2024","author":"AJ Espay","year":"2024","unstructured":"Espay AJ, Kepp KP, Herrup K. Lecanemab and donanemab as therapies for Alzheimer\u2019s disease: an illustrated perspective on the data. eNeuro. 2024. https:\/\/doi.org\/10.1523\/ENEURO.0319-23.2024.","journal-title":"eNeuro."},{"issue":"1","key":"675_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00401-022-02433-4","volume":"144","author":"ED Plowey","year":"2022","unstructured":"Plowey ED, Bussiere T, Rajagovindan R, Sebalusky J, Hamann S, von Hehn C, et al. Alzheimer disease neuropathology in a patient previously treated with aducanumab. Acta Neuropathol. 2022;144(1):143\u201353.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"675_CR21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022;9(2):197\u2013210.","journal-title":"J Prev Alzheimers Dis."},{"key":"675_CR22","unstructured":"AlzForum. Two new deaths on leqembi highlight need to better manage ARIA. https:\/\/www.alzforum.org\/news\/conference-coverage\/two-new-deaths-leqembi-highlight-need-better-manage-aria. Accessed 29 Aug 2024."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00675-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-024-00675-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00675-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T16:18:38Z","timestamp":1737821918000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-024-00675-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,2]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["675"],"URL":"https:\/\/doi.org\/10.1007\/s40120-024-00675-w","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,2]]},"assertion":[{"value":"30 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alessandro Martorana, Chiara Giuseppina Bonomi, Martina Gaia Di Donna, and Caterina Motta have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}